Ingenza
5
854K
1
0.26
0.80
- Areas of investment
Summary
Ingenza is the famous Corporate Investor, which was founded in 2002. The main department of described Corporate Investor is located in the Edinburgh. The company was established in Europe in United Kingdom.
The fund is generally included in less than 2 deals every year. The important activity for fund was in 2013. The common things for fund are deals in the range of 100 thousands - 1 million dollars.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Ingenza, startups are often financed by Kelvin Capital, Scottish Enterprise, Lancaster Capital. The meaningful sponsors for the fund in investment in the same round are Kelvin Capital, Scottish Enterprise, Lancaster Capital. In the next rounds fund is usually obtained by Kelvin Capital, Scottish Enterprise, Lancaster Capital.
The fund was created by Ian Fotheringham, Sinil Srivastava.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Among the most popular portfolio startups of the fund, we may highlight ProFactor Pharma. We can highlight the next thriving fund investment areas, such as Medical, Health Care.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Rounds per year
- 0.26
- Follow on index
- 0.80
- Investments by industry
- Medical (5)
- Biotechnology (5)
- Health Care (5)
- Investments by region
-
- United Kingdom (5)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ProFactor Pharma | 31 Aug 2013 | Biotechnology, Health Care, Medical | Seed | 822K | United Kingdom, Scotland |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.